Affiliation:
1. Unité des Toxines et Pathogénie Bactérienne (CNRS URA 2172), Institut Pasteur, 75725 Paris Cedex 15, France
Abstract
ABSTRACT
Anthrax is caused by
Bacillus anthracis
, a gram-positive spore-forming bacterium. Septicemia and toxemia rapidly lead to death in infected mammal hosts. Currently used acellular vaccines against anthrax consist of protective antigen (PA), one of the anthrax toxin components. However, in experimental animals such vaccines are less protective than live attenuated strains. Here we demonstrate that the addition of formaldehyde-inactivated spores (FIS) of
B. anthracis
to PA elicits total protection against challenge with virulent
B. anthracis
strains in mice and guinea pigs. The toxin-neutralizing activities of sera from mice immunized with PA alone or PA plus FIS were similar, suggesting that the protection conferred by PA plus FIS was not only a consequence of the humoral response to PA. A PA-deficient challenge strain was constructed, and its virulence was due solely to its multiplication. Immunization with FIS alone was sufficient to protect mice partially, and guinea pigs totally, against infection with this strain. This suggests that spore antigens contribute to protection. Guinea pigs and mice had very different susceptibilities to infection with the nontoxigenic strain, highlighting the importance of verifying the pertinence of animal models for evaluating anthrax vaccines.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Immunology,Microbiology,Parasitology
Reference36 articles.
1. Berthier, M., J. L. Fauchère, J. Perrin, B. Grignon, and D. Oriot. 1996. Fulminant meningitis due to Bacillus anthracis in 11-year-old girl during Ramadan. Lancet347:828.
2. Role of Toxin Functional Domains in Anthrax Pathogenesis
3. Attenuated Nontoxinogenic and Nonencapsulated Recombinant
Bacillus anthracis
Spore Vaccines Protect against Anthrax
4. Fellows, P. F., M. K. Linscott, B. E. Ivins, M. L. Pitt, C. A. Rossi, P. H. Gibbs, and A. M. Friedlander. 2001. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine19:3241-3247.
5. Friedlander, A. M., P. R. Pittman, and G. W. Parker. 1999. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA282:2104-2106.
Cited by
132 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献